Six cases of hepatic fascioliasis

Authors

  • Susana Galretas Serviço de Medicina III dos Hospitais da Universidade de Coimbra
  • Marta Laïz Serviço de Medicina III dos Hospitais da Universidade de Coimbra
  • Adélia Simão Serviço de Medicina III dos Hospitais da Universidade de Coimbra
  • Armando Carvalho Serviço de Medicina III dos Hospitais da Universidade de Coimbra
  • Adriano Rodrigues Serviço de Medicina III dos Hospitais da Universidade de Coimbra
  • Anabela Sá Serviço de Medicina III dos Hospitais da Universidade de Coimbra
  • Arsénio Santos Serviço de Medicina III dos Hospitais da Universidade de Coimbra
  • Rui Santos Serviço de Medicina III dos Hospitais da Universidade de Coimbra
  • J. A. P. da Silva Serviço de Medicina III dos Hospitais da Universidade de Coimbra
  • Conceição Reis Serviço de Medicina III dos Hospitais da Universidade de Coimbra
  • Eurico Almiro Serviço de Medicina III dos Hospitais da Universidade de Coimbra
  • Armando Porto Director do Serviço de Medicina III dos H.U.C.; Professor Catedrático da Faculdade de Medicina de Coimbra

Keywords:

hepatic fascioliasis, diagnosis, triclabendazole

Abstract

Fascioliasis is an infectious disease, caused by the fluke Fasciola hepatica, that mainly parasitises herbivorous animals. Man is an accidental host. Infection results from eating raw aquatic vegetables with encysted metacercariae.
The authors report 6 cases of human hepatic fascioliasis, admitted in the University of Coimbra hospital, Medicine III Service, in the last 15 years. Of the six cases, 4 were males and 2 females, with a mean age of 57 years. The most
frequent symptom was abdominal pain and the most frequent sign was jaundice. Complaints
lasted, on average, 1.6 months. Four patients confirmed recent ingestion of raw watercress.
All had eosinophilia and altered liver function tests. Abdominal ultrasound and computed
tomography scan suggested neoplasia in 3 patients, which made the diagnosis more difficult. The diagnosis was made on a positive
parasitological examination of stool specimens.
All patients had chronic fascioliasis. Five were treated with praziquantel; in 4 it was ineffective
and they had to be re-treated, 2 with bithionol and 2 with dihydroemetine. The most recently
diagnosed patient was treated with a single dose of triclabendazole.

Downloads

Download data is not yet available.

References

Lecour H. Fasciolíase Hepática. Rev Port Doenç Infec 1989:12:21-28.

Rombert PC, Grácio MAA. Surto epidémico de Fasciolíase Hepática Humana. O Médico 1990:122: 706-707.

Rombert PC, Grácio MA. Fasciolíase Hepática Humana: sua distribuição em Portugal. O Médico 1984: 110: 77-83.

El-Newihi HM, Waked IA, Milhas AA. Biliary complications of Fasciola hepatica: the role of endoscopic retrograde cholangiography in

management. J Clin Gastroenterol 1995:21(4):309-311.

WHO: Triclabendazole and fascioliasis – a new drug to combat na age-old disease. Fact sheet nº191; April 1998. Disponível em http://www.

who.int/inf-fs/en/fact191.htlm

Montembault S, Serfaty L, Poirot JL, Wendum D, Penna C, Poupon R. Ascite hémorragique révélant une infection massive à Fasciola hepatica. Gastroenterol. Clin Biol 1997:21(10):785-788.

Romão Z, Rosa A, Portela F et al. Novo tratamento para a Fasciolíase Hepática com triclabendazol. Rev Gastrenterol Cir 1998:15(78):144-

Carmo G, Viegas C, Abreu J, Lobo O, Antunes F, Távora I. Triclabendazol no tratamento da Fasciolíase Hepática Humana - a propósito de

um caso clínico. Rev Port Doenç Infec 1997:20(2):44-47.

Dias LM, Silva R, Viana HL, Palhinhas M, Viana RL. Biliary fascioliasis: diagnosis, treatment and follow-up by ERCP. Gastrointest Endosc

:43(6):616-620.

Nash TE. Schistosomiasis and other trematode infections. Chap. 224. Fauci AS. Braunwald E, Isselbacker KJ, Wilson J, Martin J, Kasper

J, Hauser J, Longo J. eds. Harrison´s Principles of Internal Medicine. New York: McGraw Hill 1998:1217-1224.

Mas-Coma MS, Esteban JG, Bargues MD. Epidemiology of human fascioliasis: a review and proposed new classification. Bull World

Health Organ 1999:77(4):340-346.

Nozais JP, Thomas I, Bricaire F, Danis M, Gentilini M. A propos d´un cas de fasciolose hépato-gastrique en provenance du Cap-Vert. Bull

Soc Pathol Exot. 1998:91(2):148-150.

Tavares C, Freitas P, Afonso C. Fasciolíase Hepática. Acta Med Port 1997:10(2-3):213-216.

Auna-Soto R. Human fascioliasis: seasonal variations and female preponderance of complicated forms. J Infect 1998:37(1):88-89.

Montero LC, Fernandez FC, Quirós JFB, Parra F. Tratamiento de fasciolasis humana con triclabendazol. Rev Clin Esp 1999:199(5):333-

Espino AM, Diaz A, Perez A, Finlay CM. Dynamics of antigenemia and coproantigens during a human Fasciola hepatica outbreak. J Clin

Microbiol 1998:36(9):2723-2726.

Porto A, Filipe A. O impacto da ecografia na Medicina Interna. Acta Radiol Port 1991:2:41-45

Sousa PJAS, Monteiro BC, Coelho JPS, Franco J, Murinello AG. Fasciolíase hepática: aspectos ecográficos e tomodensitométricos (a propósito de quatro casos clínicos). Acta Radiol Port 1989:I(1) 53-56.

Queneau PE, Koch S, Bresson-Hadni S et al. Gastroenterol Clin Biol. 1997:21(6-7):511-513.

Sanford JP, Gilbert DN, Moellering RC, Sande MA. The Sanford guide to antimicrobial theraphy, 14th ed of the Belgian/Luxembourg version, 2000-2001:133,136.

Veloso T, Rodrigues AC, Fonseca I et al. Triclabendazol na Fasciolíase Hepática - a propósito de um caso clínico. Rev Port Doenç Infec

:17(4):255-257.

Abreu F, Aidos A, Rebelo I, Lacerda C, Palminha JM. Utilização do Bithionol para a fasciolíase num caso de multiparasitismo hepático.

Rev Port Doenç Infec. 1995:18(3/4):252-258.

Oliveira L, Corredoura AS, Beato V et al. Fasciolíase hepática humana tratada com triclabendazol. Medicina Interna 2002:9:39-42

Apt W, Aguilera X, Vega F et al. Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response. Am

J Trop Med Hyg 1995:52(6):532-535.

Wesseley K, Reischig HL, Heinermann M, Stempka R. Human fascioliasis treated with triclabendazole (Fasinex®) for the first time. Tran R

Soc Trop Med Hyg 1988:82:743-745.

Lopez-Velez R, Dominguez-Castellano A, Garrón C. Successful treatment of human fascioliasis with triclabendazole. Eur J Clin Microbiol

Infec Dis 1999:18(7):525-526.

Yilmaz H, Oner AF, Akdeniz H, Arlan S. The effect of triclabendazole (Fasinex) in children with fascioliasis. J Egypt Soc Parasitol

:28(2):497-502 (abstract).

El-Karaksy H, Hassanein B, Okasha S, Behairy B, Gadallah I. Human fascioliasis in Egyptian children: successful treatment with triclabendazole. J Trop Pediatr 1999 :45(3):135-138 (abstract).

Gavinet MF, Dousset B, Puechal X et al. Hepatic distomatosis of tumour form after prolonged treatment with corticoids. Gastroenterol Clin Biol 1997:21(3):219-222.

Dowidar N, Sayad EM, Osman M, Salem A. Endoscopic therapy of fascioliasis resistant to oral therapy. Gastrointest Endosc 1999:50(3):345-

El-Sayad MH, Allam AF, Osman MM. Prevention of human fascioliasis: a study on the role of acids detergents and potassium permenganate in clearing salads from metacercariae. J Egypt Soc Parasitol 1997:27(1):163-169 (abstract)

Additional Files

Published

2003-12-31

How to Cite

1.
Galretas S, Laïz M, Simão A, Carvalho A, Rodrigues A, Sá A, Santos A, Santos R, da Silva JAP, Reis C, Almiro E, Porto A. Six cases of hepatic fascioliasis. RPMI [Internet]. 2003 Dec. 31 [cited 2024 May 18];10(4):185-92. Available from: https://revista.spmi.pt/index.php/rpmi/article/view/1828

Issue

Section

Original Articles

Most read articles by the same author(s)

<< < 1 2 3 4 > >>